Investment analysts at MLV Capital started coverage on shares of Pluristem Therapeutics (NASDAQ: PSTI) in a note issued to investors on Friday, TheFlyOnTheWall.com reports. The firm set a “buy” rating and a $4.50 price target on the stock. MLV Capital’s price target would indicate a potential upside of 43.31% from the company’s current price.
The analysts wrote, “We are initiating coverage of Pluristem Therapeutics based on accumulating, though early, evidence of efficacy and safety of its proprietary cell therapy products advancing into later stage clinical trials this year and next. Moreover, the company’s proprietary and cost-effective three-dimensional cell production system can supply cells for ongoing and planned clinical trials. In our view, the combination of a deep pipeline for multiple high value indications, ownership and control of producing its cell therapy product, and a secure financial position, distinguishes Pluristem from many of its competitors. With the company’s stock trading in a narrow range for several months and with upcoming milestones, we think the company is approaching an inflection point. We are initiating coverage of Pluristem with a BUY recommendation and a $4.50 one-year price target.”
Separately, analysts at Jefferies Group initiated coverage on shares of Pluristem Therapeutics in a research note to investors on Monday, March 18th. They set a “hold” rating and a $3.50 price target on the stock.
Shares of Pluristem Therapeutics (NASDAQ: PSTI) opened at 3.14 on Friday. Pluristem Therapeutics has a one year low of $2.26 and a one year high of $5.00. The stock’s 50-day moving average is currently $3.09. The company’s market cap is $184.1 million.
Pluristem Therapeutics Inc. (NASDAQ: PSTI) is a bio-therapeutics company engaged in the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with Analyst Ratings Network's FREE daily email newsletter.